EHA 2021 | FLT3 inhibitors as maintenance therapy in AML
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, talks on the use of FMS-like tyrosine kinase 3 (FLT3) inhibitors for maintenance therapy in acute myeloid leukemia (AML). Sorafenib has been shown to improve relapse-free survival in patients with AML and a FLT3 internal tandem duplication (FLT3-ITD) mutation. However, recent trials, such as the MORPHO trial (NCT02997202) have investigated whether FLT3 inhibitors such as gilteritinib are necessary after allogenic hematopoietic stem cell transplant (allo-HSCT). Dr Levis discusses the findings of these studies and comments on how measurable residual disease (MRD) could be used as an indicator for which patients are suitable for FLT3 inhibitor maintenance therapy. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
